The upcoming earnings report for TFX is scheduled for Wednesday, May 6th, with a consensus estimate EPS of 1.21.
Teleflex Incorporated (TFX) is currently priced at $135.43, showing a price change of 35.5 cents (0.263%) from the previous close. Trading volume is at $125,063, representing a 13.14% increase over the average.
TFX has experienced a three-day streak with a price decrease of $3.38 (-2.44%) since the streak started at $138.81.
In its latest quarterly earnings on Wednesday, February 25th, TFX reported a consensus estimate EPS of 3.73 and a consensus estimate revenue of 912.57 million.
TFX offers a dividend per share of 34 cents MRQ, with a forward dividend yield of 1% and a TTM dividend per share of $1.36.
The company's operating cash flow stands at $152.21 million, with a net change in cash of $9.87 million, ending the period with $378.56 million in cash.
TFX reported a net income of -$714.33 million, with an EPS and diluted EPS of -$16.15. The revenue was $568.98 million, with a gross profit of $307.45 million.
Notable ratios include a quick ratio of 2.01, gross profit margin of 54.03%, and return on equity of -22.86.
TFX shows total assets of $6.95 billion and total liabilities of $3.82 billion, with net debt at $2.33 billion.
This comprehensive overview provides insights into TFX's financial performance and outlook.
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site. The company also offers interventional products, which consists of various coronary catheters, structural heart therapies, and peripheral intervention and cardiac assist products that are used by interventional cardiologists and radiologists, and vascular surgeons; and Arrow branded catheters, Guideline and Trapliner catheters, the Manta Vascular Closure, and Arrow Oncontrol devices. It provides anesthesia products, such as airway and pain management products to support hospital, emergency medicine, and military channels; and surgical products, including metal and polymer ligation clips, and fascial closure surgical systems that are used in laparoscopic surgical procedures, percutaneous surgical systems, and other surgical instruments. The company also offers interventional urology products comprising the UroLift System, an invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia; and respiratory products, including oxygen and aerosol therapies, spirometry, and ventilation management products for use in various care settings. It provides urology products, such as catheters, urine collectors, and catheterization accessories and products for operative endourology; and bladder management services. The company serves hospitals and healthcare providers, medical device manufacturers, and home care markets. The company was incorporated in 1943 and is headquartered in Wayne, Pennsylvania.